Visus Therapeutics Announces Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL PF™ for the Treatment of Presbyopia
Press Release Visus Therapeutics Inc., a clinical-stage pharmaceutical company, focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today reported positive topline results from its Phase 3 pivotal BRIO-I trial….
Source: venturebeat.com